MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
8.68
-0.01
-0.12%
After Hours: 8.76 +0.08 +0.92% 19:58 12/19 EST
OPEN
8.44
PREV CLOSE
8.69
HIGH
9.04
LOW
8.37
VOLUME
4.83M
TURNOVER
--
52 WEEK HIGH
12.34
52 WEEK LOW
2.235
MARKET CAP
495.93M
P/E (TTM)
-2.3184
1D
5D
1M
3M
1Y
5Y
1D
Top Executive Makes Notable Move in 4D Molecular Therapeutics Stock
TipRanks · 1d ago
4D Molecular Therapeutics Inc. Files Initial Beneficial Ownership Statement for Officer Christopher Paul Simms
Reuters · 1d ago
Chief Legal Officer Scott Bizily Reports Disposal of 4D Molecular Therapeutics Inc. Common Shares
Reuters · 1d ago
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop
Seeking Alpha · 2d ago
BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT)
TipRanks · 2d ago
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 3d ago
4D Molecular Therapeutics Price Target Maintained With a $26.00/Share by Chardan Capital
Dow Jones · 3d ago
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.